Neuraxpharm Buccolam Acquisition Opens Up Opportunities

Strikes Deal With Takeda For The Only Buccal Midazolam Approved Across Europe

Neuraxpharm says a deal with Takeda to acquire the only buccal midazolam approved across Europe, Buccolam, not only gives the CNS specialist a strong asset but also offers the opportunity to expand its commercial footprint into the Nordics and Ireland.

Neuraxpharm
Neuraxpharm has struck a deal with Takeda for buccal midazolam • Source: Shutterstock

Neuraxpharm has struck a deal to acquire Buccolam (midazolam), “the only buccal midazolam approved across Europe,” from Takeda in a move that the central nervous system specialist says will strengthen its position in several European countries while also offering the opportunity to expand its footprint into markets such as the Nordics and Ireland.

More from Deals

Kabi Widens The Net With US Aflibercept Deal, As Amgen Biosimilar Hearing Nears

 
• By 

Fresenius Kabi is to diversify its offering beyond immunology and oncology after putting pen to paper on a deal for a US biosimilar to Eylea, in the wake of Amgen’s surprise at-risk launch.

Bio-Thera Picks Tabuk As Stelara Biosimilar Partner In Saudi Arabia

2024 was truly a dealmaking year for Bio-Thera, with the latest partnership expanding the net for its ustekinumab biosimilar.

Bio-Thera Expands Latin America Deal With SteinCares

 
• By 

Chinese biosimilars developer Bio-Thera is expanding its Latin American partnership with SteinCares with the addition of a third product.

Torrent Picks Up Boehringer Diabetes Brands Ahead Of India Patent Expiry

 
• By 

Boehringer Ingelheim’s sale of three diabetes brands in India, with the same composition as Jardiance, Jardiance Met and Glyxambi, to Torrent comes ahead of the expiry of the Indian patent for empagliflozin. A launch for other indications is also expected.

More from Business

‘Everyone Thinks Generics And Biosimilars Is Easy’ – Sandoz’s Saynor Talks Evolution Of Core Businesses

 
• By 

In the second part of our exclusive interview with Richard Saynor, the Sandoz CEO discusses the importance of both the small-molecule generics and biosimilars businesses for the company, talking about portfolio selection and specific product opportunities for biosimilars while also contrasting the firm’s European and US generics leadership aspirations and approaches to the business.

‘This Was Always Going To Be A Multi-Year Journey’ – Sandoz’s CEO On The Road Ahead

 
• By 

In the first instalment of a three-part interview with Richard Saynor, the Sandoz CEO talks about the aftermath of the company’s spinoff from former parent Novartis and the work still left to do; the increasing prominence of biosimilars for Sandoz; the firm’s investments in manufacturing; thoughts on the potential for significant M&A; and future opportunities for the industry leader.

Generics Industry Hungry For More After Showing Larger GLP-1 Appetite In 2024

 
• By 

GLP-1 drugs like Ozempic and Mounjaro have shaken up pharma, crossing firmly over into the mainstream while netting fortunate suppliers billions of dollars in the process. As patent expiry approaches for first- and second-generation products, generics manufacturers are gearing up to take a share of the spoils.